Financial Summary (All financials)
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
Revenues | 5,825.7 | 5,254.7 | 4,634.4 | 4,563.9 | 3,800.4 | 5,756.1 | 5,378.2 | 6,178.8 |
Revenue growth | 10.9% | 13.4% | 1.5% | 20.1% | -34.0% | 7.0% | -13.0% | -2.5% |
Cost of goods sold | 2,462.3 | 2,247.6 | 2,025.9 | 2,080.7 | 1,614.2 | 2,834.7 | 2,692.7 | 3,178.8 |
Gross profit | 3,363.4 | 3,007.1 | 2,608.5 | 2,483.2 | 2,186.2 | 2,921.4 | 2,685.5 | 3,000.0 |
Gross margin | 57.7% | 57.2% | 56.3% | 54.4% | 57.5% | 50.8% | 49.9% | 48.6% |
Selling, general and administrative | 1,956.6 | 1,839.5 | 1,748.4 | 1,719.0 | 1,262.8 | 1,409.1 | 1,272.8 | 1,352.6 |
Research and development | 401.5 | 354.8 | 320.7 | 320.3 | 278.1 | 369.3 | 351.0 | 377.7 |
EBITA | 1,369.4 | 1,152.5 | 876.2 | 755.3 | 754.8 | 1,226.6 | 1,166.9 | 1,383.0 |
EBITA margin | 23.5% | 21.9% | 18.9% | 16.5% | 19.9% | 21.3% | 21.7% | 22.4% |
Amortization of intangibles | 382.0 | 321.0 | 310.0 | 261.0 | 105.0 | 65.0 | 85.0 | 89.0 |
EBIT | 987.4 | 831.5 | 566.2 | 494.3 | 649.8 | 1,161.6 | 1,081.9 | 1,294.0 |
EBIT margin | 16.9% | 15.8% | 12.2% | 10.8% | 17.1% | 20.2% | 20.1% | 20.9% |
Pre-tax income | 873.5 | 677.5 | 1,507.7 | 336.7 | 565.8 | 1,073.6 | 1,010.5 | 1,269.7 |
Income taxes | 118.3 | 63.3 | 55.5 | 68.6 | 75.6 | 189.3 | 270.3 | 405.9 |
Tax rate | 13.5% | 9.3% | 3.7% | 20.4% | 13.4% | 17.6% | 26.7% | 32.0% |
Earnings from continuing ops | 755.2 | 579.7 | 1,383.2 | 199.1 | 455.3 | 884.3 | 740.2 | 863.8 |
Earnings from discontinued ops | | -5.8 | 161.1 | 470.8 | 2,423.6 | 160.2 | 132.1 | |
Net income | 755.2 | 573.9 | 1,544.3 | 669.9 | 2,878.9 | 1,044.5 | 872.3 | 863.8 |
Net margin | 13.0% | 10.9% | 33.3% | 14.7% | 75.8% | 18.1% | 16.2% | 14.0% |
|
Diluted EPS | $2.09 | $1.65 | $3.85 | $0.59 | $1.30 | $2.51 | $2.13 | $2.50 |
Shares outstanding (diluted) | 360.8 | 352.3 | 359.0 | 340.0 | 350.7 | 352.6 | 347.3 | 345.2 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|